Peginterferon alfa-2a (40 KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double blind, multicentre study examining effects of duration of treatment and RBV dose - Hadziyannis,S.J.; Cheinquier,H.; Morgan,T. (J Hepatol, 2002)